323 related articles for article (PubMed ID: 28423632)
1. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Li X; Zhang R; Liu Z; Li S; Xu H
Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
[TBL] [Abstract][Full Text] [Related]
2. Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
Lin L; Zhang Z; Zhang W; Wang L; Wang J
Int J Clin Exp Pathol; 2015; 8(10):13314-22. PubMed ID: 26722535
[TBL] [Abstract][Full Text] [Related]
3. Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population.
Zhang Z; Chen Q; Zhang J; Wang Y; Hu X; Yin S; He M; Guan S; Qin W; Xiao Q; Zhao H; Yao W; Wu H; Wei M
Sci Rep; 2017 Dec; 7(1):17844. PubMed ID: 29259266
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
5. A GG allele of 3'-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer.
Wang X; Lin Y; Lan F; Yu Y; Ouyang X; Wang X; Huang Q; Wang L; Tan J; Zheng F
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1399-411. PubMed ID: 24737346
[TBL] [Abstract][Full Text] [Related]
6. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
7. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
[TBL] [Abstract][Full Text] [Related]
8. Association between
Wang Z; Fu H; Li W
Oncol Lett; 2018 Sep; 16(3):3699-3705. PubMed ID: 30127980
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
[TBL] [Abstract][Full Text] [Related]
10. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
[TBL] [Abstract][Full Text] [Related]
11. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
12. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
13. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
16. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
[TBL] [Abstract][Full Text] [Related]
17. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
[TBL] [Abstract][Full Text] [Related]
18. A Functional Polymorphism (rs2494752) in the AKT1 Promoter Region and Gastric Adenocarcinoma Risk in an Eastern Chinese Population.
Wang MY; He J; Zhu ML; Teng XY; Li QX; Sun MH; Wang XF; Yang YJ; Wang JC; Jin L; Wang YN; Wei QY
Sci Rep; 2016 Jan; 6():20008. PubMed ID: 26818920
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
